| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 21 | 2025 | 855 | 2.910 |
Why?
|
| Glioma | 12 | 2023 | 321 | 2.250 |
Why?
|
| Muscle, Skeletal | 14 | 2018 | 483 | 1.340 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2024 | 539 | 1.120 |
Why?
|
| Mutation | 15 | 2025 | 4374 | 0.980 |
Why?
|
| Autopsy | 5 | 2021 | 129 | 0.950 |
Why?
|
| Brain | 9 | 2021 | 2482 | 0.950 |
Why?
|
| Neuroblastoma | 7 | 2021 | 400 | 0.930 |
Why?
|
| Muscular Diseases | 5 | 2018 | 68 | 0.910 |
Why?
|
| Myasthenic Syndromes, Congenital | 6 | 2021 | 36 | 0.780 |
Why?
|
| Humans | 108 | 2025 | 96093 | 0.770 |
Why?
|
| Biopsy | 7 | 2024 | 1220 | 0.750 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2020 | 91 | 0.750 |
Why?
|
| Biomarkers, Tumor | 8 | 2025 | 1664 | 0.720 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2020 | 99 | 0.710 |
Why?
|
| Megakaryocytes | 1 | 2021 | 39 | 0.710 |
Why?
|
| Telomerase | 1 | 2021 | 68 | 0.700 |
Why?
|
| Placenta | 2 | 2022 | 191 | 0.700 |
Why?
|
| Microvessels | 1 | 2021 | 74 | 0.690 |
Why?
|
| Alzheimer Disease | 4 | 2017 | 606 | 0.690 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 68 | 0.670 |
Why?
|
| Astrocytoma | 4 | 2025 | 89 | 0.650 |
Why?
|
| Immunohistochemistry | 14 | 2022 | 1828 | 0.650 |
Why?
|
| Pathology, Surgical | 1 | 2019 | 13 | 0.630 |
Why?
|
| Microbiological Techniques | 1 | 2019 | 25 | 0.620 |
Why?
|
| Cerebellar Neoplasms | 3 | 2017 | 45 | 0.590 |
Why?
|
| Rhabdoid Tumor | 2 | 2016 | 21 | 0.580 |
Why?
|
| Membrane Proteins | 11 | 2025 | 1276 | 0.570 |
Why?
|
| Schwann Cells | 3 | 2020 | 34 | 0.570 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 39 | 0.570 |
Why?
|
| Male | 52 | 2025 | 45870 | 0.570 |
Why?
|
| Neurilemmoma | 2 | 2021 | 41 | 0.550 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2018 | 307 | 0.550 |
Why?
|
| Hemangioblastoma | 2 | 2017 | 15 | 0.550 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 9 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 45 | 0.530 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 465 | 0.530 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 52 | 0.520 |
Why?
|
| Female | 56 | 2025 | 50030 | 0.520 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 85 | 0.510 |
Why?
|
| Muscular Dystrophies | 4 | 2013 | 55 | 0.500 |
Why?
|
| Glioblastoma | 4 | 2015 | 286 | 0.500 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 553 | 0.500 |
Why?
|
| Neoplasms | 2 | 2022 | 3248 | 0.500 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2016 | 3 | 0.490 |
Why?
|
| Glycogen Storage Disease | 1 | 2016 | 5 | 0.490 |
Why?
|
| Myoepithelioma | 1 | 2015 | 10 | 0.480 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2020 | 126 | 0.480 |
Why?
|
| Middle Aged | 33 | 2025 | 28361 | 0.480 |
Why?
|
| Myofibrils | 2 | 2014 | 22 | 0.460 |
Why?
|
| Niemann-Pick Disease, Type C | 1 | 2015 | 5 | 0.460 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2015 | 109 | 0.450 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 453 | 0.450 |
Why?
|
| Complement C4 | 1 | 2014 | 8 | 0.440 |
Why?
|
| Sella Turcica | 2 | 2019 | 17 | 0.440 |
Why?
|
| Nerve Sheath Neoplasms | 3 | 2020 | 22 | 0.440 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2014 | 21 | 0.440 |
Why?
|
| Myositis | 1 | 2014 | 18 | 0.440 |
Why?
|
| Vesicular Transport Proteins | 4 | 2018 | 70 | 0.430 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 172 | 0.430 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 111 | 0.430 |
Why?
|
| MAP Kinase Signaling System | 2 | 2025 | 206 | 0.430 |
Why?
|
| Pituitary Neoplasms | 2 | 2019 | 74 | 0.420 |
Why?
|
| Muscle Proteins | 7 | 2014 | 134 | 0.420 |
Why?
|
| Temporal Lobe | 1 | 2015 | 195 | 0.420 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 15 | 0.420 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2014 | 42 | 0.410 |
Why?
|
| Paraganglioma | 2 | 2019 | 16 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 98 | 0.380 |
Why?
|
| Adolescent | 13 | 2025 | 9896 | 0.370 |
Why?
|
| Seizures | 1 | 2015 | 331 | 0.370 |
Why?
|
| Aged | 22 | 2025 | 20962 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 406 | 0.360 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 2059 | 0.360 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 7230 | 0.360 |
Why?
|
| Organ Transplantation | 1 | 2015 | 298 | 0.360 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 359 | 0.360 |
Why?
|
| Hippocampus | 1 | 2015 | 459 | 0.350 |
Why?
|
| Child | 15 | 2025 | 7626 | 0.350 |
Why?
|
| Cardiomyopathies | 5 | 2024 | 289 | 0.350 |
Why?
|
| Adult | 27 | 2025 | 28716 | 0.350 |
Why?
|
| Neurofibromatosis 1 | 2 | 2022 | 45 | 0.350 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2017 | 153 | 0.320 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 16 | 0.320 |
Why?
|
| Pinealoma | 2 | 2024 | 6 | 0.310 |
Why?
|
| Child, Preschool | 11 | 2024 | 3974 | 0.310 |
Why?
|
| Pneumocephalus | 1 | 2009 | 12 | 0.310 |
Why?
|
| Embolism, Air | 1 | 2009 | 24 | 0.310 |
Why?
|
| Nervous System Neoplasms | 1 | 2009 | 11 | 0.310 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2009 | 1 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 1089 | 0.300 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2025 | 367 | 0.300 |
Why?
|
| Retrospective Studies | 8 | 2024 | 10286 | 0.300 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2008 | 4 | 0.300 |
Why?
|
| Craniopharyngioma | 1 | 2009 | 13 | 0.300 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2018 | 138 | 0.290 |
Why?
|
| World Health Organization | 1 | 2009 | 122 | 0.290 |
Why?
|
| Mice | 30 | 2024 | 12538 | 0.290 |
Why?
|
| Diagnosis, Differential | 8 | 2021 | 1619 | 0.290 |
Why?
|
| Transcription Factors | 4 | 2022 | 1730 | 0.290 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 2550 | 0.290 |
Why?
|
| Nerve Tissue Proteins | 6 | 2018 | 515 | 0.290 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2008 | 11 | 0.290 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 70 | 0.290 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2008 | 67 | 0.280 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 107 | 0.280 |
Why?
|
| Laminin | 3 | 2018 | 92 | 0.280 |
Why?
|
| Young Adult | 9 | 2025 | 7025 | 0.270 |
Why?
|
| Oligodendroglia | 2 | 2020 | 122 | 0.270 |
Why?
|
| Hemorrhage | 1 | 2009 | 294 | 0.270 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 750 | 0.260 |
Why?
|
| Dacarbazine | 3 | 2013 | 101 | 0.260 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2007 | 21 | 0.260 |
Why?
|
| Animals | 35 | 2024 | 28914 | 0.250 |
Why?
|
| Signal Transduction | 5 | 2025 | 3581 | 0.250 |
Why?
|
| rho-Associated Kinases | 2 | 2019 | 162 | 0.250 |
Why?
|
| Nuclear Envelope | 3 | 2024 | 39 | 0.250 |
Why?
|
| Dementia, Vascular | 1 | 2006 | 6 | 0.240 |
Why?
|
| DNA Methylation | 4 | 2025 | 703 | 0.240 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 1267 | 0.240 |
Why?
|
| Cerebral Infarction | 1 | 2006 | 74 | 0.230 |
Why?
|
| Ovarian Neoplasms | 2 | 2023 | 800 | 0.230 |
Why?
|
| Ganglioneuroma | 1 | 2005 | 9 | 0.230 |
Why?
|
| Cauda Equina | 1 | 2005 | 13 | 0.230 |
Why?
|
| Liposarcoma | 1 | 2005 | 11 | 0.220 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2017 | 38 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 555 | 0.220 |
Why?
|
| Sepsis | 1 | 2009 | 391 | 0.220 |
Why?
|
| Spinal Diseases | 1 | 2006 | 99 | 0.220 |
Why?
|
| Dura Mater | 2 | 2020 | 51 | 0.220 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2019 | 259 | 0.220 |
Why?
|
| Pineal Gland | 1 | 2024 | 16 | 0.220 |
Why?
|
| Neuromuscular Junction | 3 | 2021 | 82 | 0.220 |
Why?
|
| Infant | 8 | 2020 | 3363 | 0.220 |
Why?
|
| ErbB Receptors | 2 | 2021 | 513 | 0.210 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 33 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2025 | 224 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 180 | 0.210 |
Why?
|
| Amyloid beta-Peptides | 2 | 2021 | 246 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2020 | 3651 | 0.210 |
Why?
|
| Stress, Physiological | 2 | 2020 | 252 | 0.200 |
Why?
|
| Myoblasts | 4 | 2014 | 33 | 0.200 |
Why?
|
| Kidney Neoplasms | 2 | 2025 | 558 | 0.200 |
Why?
|
| Cell Count | 2 | 2021 | 203 | 0.200 |
Why?
|
| Motor Neurons | 2 | 2017 | 178 | 0.200 |
Why?
|
| Fatal Outcome | 5 | 2013 | 304 | 0.200 |
Why?
|
| Lymphoma | 2 | 2018 | 271 | 0.190 |
Why?
|
| Radiation Injuries | 1 | 2024 | 163 | 0.190 |
Why?
|
| Vasculitis | 2 | 2020 | 40 | 0.190 |
Why?
|
| Spinal Nerve Roots | 1 | 2002 | 21 | 0.190 |
Why?
|
| Neurofibromatoses | 1 | 2002 | 13 | 0.190 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2002 | 10 | 0.190 |
Why?
|
| Myocardium | 3 | 2018 | 596 | 0.190 |
Why?
|
| Myocytes, Cardiac | 2 | 2024 | 324 | 0.190 |
Why?
|
| Teratoma | 1 | 2023 | 58 | 0.190 |
Why?
|
| Extracellular Matrix | 1 | 2024 | 255 | 0.190 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 58 | 0.190 |
Why?
|
| Tissue Fixation | 1 | 2022 | 40 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 3 | 2021 | 992 | 0.190 |
Why?
|
| Formaldehyde | 1 | 2022 | 53 | 0.190 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 79 | 0.190 |
Why?
|
| Intracranial Hemorrhages | 2 | 2024 | 136 | 0.190 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 2 | 2021 | 2 | 0.180 |
Why?
|
| Monosomy | 1 | 2022 | 12 | 0.180 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 6 | 0.180 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 6 | 0.180 |
Why?
|
| Muscle Development | 2 | 2014 | 45 | 0.180 |
Why?
|
| Chondrosarcoma | 1 | 2022 | 54 | 0.180 |
Why?
|
| Specimen Handling | 1 | 2022 | 109 | 0.180 |
Why?
|
| Synaptotagmin II | 1 | 2021 | 1 | 0.180 |
Why?
|
| Chloroquine | 1 | 2021 | 12 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 11 | 0.180 |
Why?
|
| Pelvic Neoplasms | 2 | 2012 | 45 | 0.170 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 9 | 0.170 |
Why?
|
| Antimalarials | 1 | 2021 | 21 | 0.170 |
Why?
|
| Tissue Array Analysis | 2 | 2013 | 132 | 0.170 |
Why?
|
| Workflow | 1 | 2021 | 80 | 0.170 |
Why?
|
| Quinine | 1 | 2001 | 7 | 0.170 |
Why?
|
| Cobalt | 1 | 2001 | 31 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 204 | 0.170 |
Why?
|
| Axons | 2 | 2020 | 189 | 0.170 |
Why?
|
| Osteosarcoma | 1 | 2022 | 160 | 0.170 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Visual Prosthesis | 1 | 2020 | 7 | 0.160 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 2 | 2019 | 36 | 0.160 |
Why?
|
| Sarcoma | 2 | 2017 | 225 | 0.160 |
Why?
|
| Neuropathology | 1 | 2020 | 2 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 1172 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2021 | 156 | 0.160 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2020 | 9 | 0.160 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2020 | 12 | 0.160 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 4 | 0.160 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2020 | 80 | 0.160 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 5 | 0.160 |
Why?
|
| Simvastatin | 2 | 2019 | 106 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 117 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2001 | 148 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 116 | 0.160 |
Why?
|
| Fasciitis | 1 | 2019 | 13 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 301 | 0.150 |
Why?
|
| Synaptic Transmission | 2 | 2018 | 233 | 0.150 |
Why?
|
| Mice, Transgenic | 8 | 2017 | 1645 | 0.150 |
Why?
|
| Myosin Heavy Chains | 4 | 2019 | 91 | 0.150 |
Why?
|
| Mucolipidoses | 1 | 2019 | 3 | 0.150 |
Why?
|
| Orbital Diseases | 1 | 2019 | 15 | 0.150 |
Why?
|
| Frozen Sections | 1 | 2019 | 50 | 0.150 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2019 | 12 | 0.150 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 80 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 59 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 319 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 2463 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 126 | 0.150 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2019 | 8 | 0.150 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 90 | 0.150 |
Why?
|
| Theilovirus | 1 | 2019 | 15 | 0.150 |
Why?
|
| Optic Chiasm | 1 | 2019 | 16 | 0.150 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2018 | 7 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 465 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2020 | 271 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 235 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2019 | 192 | 0.140 |
Why?
|
| Amyloidosis | 1 | 2020 | 139 | 0.140 |
Why?
|
| Motor Cortex | 2 | 2017 | 215 | 0.140 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 118 | 0.140 |
Why?
|
| Necrosis | 3 | 2014 | 210 | 0.140 |
Why?
|
| Lamin Type A | 2 | 2024 | 26 | 0.140 |
Why?
|
| Motor Endplate | 2 | 2018 | 29 | 0.140 |
Why?
|
| Carrier Proteins | 3 | 2010 | 683 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 1546 | 0.140 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2015 | 54 | 0.140 |
Why?
|
| Stem Cell Transplantation | 2 | 2016 | 192 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2021 | 370 | 0.140 |
Why?
|
| Inflammation | 3 | 2014 | 1068 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 3489 | 0.130 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 2777 | 0.130 |
Why?
|
| Multiple Sclerosis | 1 | 2020 | 263 | 0.130 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2017 | 3 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2021 | 3107 | 0.130 |
Why?
|
| DNA Damage | 2 | 2024 | 392 | 0.130 |
Why?
|
| Pregnancy | 2 | 2022 | 3240 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2008 | 2591 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 444 | 0.130 |
Why?
|
| Visual Cortex | 1 | 2020 | 265 | 0.130 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2017 | 16 | 0.130 |
Why?
|
| Medulloblastoma | 2 | 2009 | 44 | 0.130 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2017 | 14 | 0.130 |
Why?
|
| Polyethylene | 1 | 2016 | 7 | 0.130 |
Why?
|
| Osteolysis | 1 | 2016 | 15 | 0.130 |
Why?
|
| Cartilage Diseases | 1 | 2016 | 18 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 396 | 0.130 |
Why?
|
| Cells, Cultured | 7 | 2020 | 2940 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2025 | 547 | 0.130 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 50 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 1346 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 1469 | 0.130 |
Why?
|
| Adenoma | 1 | 2019 | 260 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 47 | 0.120 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2016 | 29 | 0.120 |
Why?
|
| Phosphofructokinases | 1 | 2016 | 2 | 0.120 |
Why?
|
| Dendrites | 1 | 2017 | 104 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1754 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2016 | 350 | 0.120 |
Why?
|
| Central Nervous System | 1 | 2017 | 154 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 657 | 0.120 |
Why?
|
| Prognosis | 6 | 2021 | 4029 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 151 | 0.120 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2614 | 0.120 |
Why?
|
| Myostatin | 1 | 2015 | 3 | 0.120 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2015 | 15 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2024 | 149 | 0.120 |
Why?
|
| White Matter | 1 | 2016 | 96 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2017 | 185 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 763 | 0.110 |
Why?
|
| Inclusion Bodies | 1 | 2015 | 33 | 0.110 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2006 | 81 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 68 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 73 | 0.110 |
Why?
|
| Osteoma | 1 | 2014 | 5 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 880 | 0.110 |
Why?
|
| Aging, Premature | 1 | 2014 | 6 | 0.110 |
Why?
|
| Tubulin | 1 | 2015 | 61 | 0.110 |
Why?
|
| Protein Transport | 5 | 2019 | 439 | 0.110 |
Why?
|
| Femoral Neoplasms | 1 | 2014 | 19 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 684 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 644 | 0.110 |
Why?
|
| Fluoxetine | 1 | 2014 | 42 | 0.110 |
Why?
|
| Mice, Knockout | 6 | 2019 | 2161 | 0.110 |
Why?
|
| Phenotype | 5 | 2024 | 2579 | 0.110 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 42 | 0.110 |
Why?
|
| Biomarkers | 3 | 2012 | 1932 | 0.110 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2014 | 11 | 0.110 |
Why?
|
| Quadriceps Muscle | 1 | 2014 | 8 | 0.110 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2014 | 38 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 102 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 170 | 0.100 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.100 |
Why?
|
| Pigmentation | 1 | 2014 | 77 | 0.100 |
Why?
|
| Caspase 9 | 1 | 2013 | 49 | 0.100 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2013 | 5 | 0.100 |
Why?
|
| Radiation | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cell Lineage | 1 | 2015 | 324 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 172 | 0.100 |
Why?
|
| Glycerol | 1 | 2013 | 37 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2017 | 464 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 209 | 0.100 |
Why?
|
| Spinal Curvatures | 1 | 2013 | 8 | 0.100 |
Why?
|
| NIMA-Related Kinases | 1 | 2013 | 7 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 164 | 0.100 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2013 | 13 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 301 | 0.100 |
Why?
|
| Microscopy, Electron | 3 | 2021 | 510 | 0.100 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dysferlin | 4 | 2015 | 14 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 49 | 0.100 |
Why?
|
| Calpain | 1 | 2013 | 113 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2014 | 348 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 589 | 0.100 |
Why?
|
| Melanoma | 1 | 2017 | 497 | 0.090 |
Why?
|
| Gene Silencing | 2 | 2013 | 181 | 0.090 |
Why?
|
| Cardiac Myosins | 2 | 2009 | 19 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 331 | 0.090 |
Why?
|
| Extremities | 1 | 2013 | 179 | 0.090 |
Why?
|
| Kisspeptins | 1 | 2011 | 4 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 198 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 159 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 701 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 156 | 0.090 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 65 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2012 | 143 | 0.090 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2013 | 197 | 0.090 |
Why?
|
| Choroid Plexus | 1 | 2011 | 16 | 0.090 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 11 | 0.090 |
Why?
|
| Intracranial Aneurysm | 1 | 2013 | 206 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 161 | 0.080 |
Why?
|
| Membrane Fusion | 1 | 2010 | 38 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2015 | 541 | 0.080 |
Why?
|
| Radiography | 3 | 2013 | 826 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 475 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 1773 | 0.080 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2010 | 3 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 771 | 0.080 |
Why?
|
| Hemangioma, Cavernous | 1 | 2011 | 69 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2015 | 477 | 0.080 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 68 | 0.080 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2010 | 17 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1533 | 0.080 |
Why?
|
| NFATC Transcription Factors | 1 | 2010 | 50 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 412 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 46 | 0.080 |
Why?
|
| Keratins | 2 | 2012 | 63 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 166 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1215 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 45 | 0.080 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2010 | 39 | 0.080 |
Why?
|
| Homozygote | 2 | 2022 | 208 | 0.080 |
Why?
|
| Age Factors | 3 | 2014 | 1963 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2009 | 18 | 0.080 |
Why?
|
| KATP Channels | 1 | 2009 | 20 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 443 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 766 | 0.080 |
Why?
|
| Hypertrophy | 2 | 2015 | 68 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2007 | 315 | 0.080 |
Why?
|
| Receptors, Drug | 1 | 2009 | 54 | 0.080 |
Why?
|
| Neocortex | 1 | 2010 | 106 | 0.080 |
Why?
|
| Brain Infarction | 1 | 2009 | 24 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 76 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 3147 | 0.080 |
Why?
|
| Sarcomeres | 1 | 2009 | 27 | 0.080 |
Why?
|
| Oligodendroglioma | 1 | 2009 | 45 | 0.080 |
Why?
|
| Genome, Human | 1 | 2014 | 824 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 528 | 0.080 |
Why?
|
| Exercise Tolerance | 1 | 2009 | 65 | 0.080 |
Why?
|
| Lung | 2 | 2021 | 1382 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 77 | 0.070 |
Why?
|
| Complement Activation | 1 | 2009 | 84 | 0.070 |
Why?
|
| Microcirculation | 1 | 2009 | 110 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 142 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 238 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2010 | 695 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 67 | 0.070 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 80 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2007 | 518 | 0.070 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2008 | 16 | 0.070 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2009 | 124 | 0.070 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2009 | 55 | 0.070 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 10 | 0.070 |
Why?
|
| Salivary Glands, Minor | 1 | 2008 | 9 | 0.070 |
Why?
|
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.070 |
Why?
|
| Bronchi | 1 | 2009 | 234 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 3 | 2017 | 444 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1666 | 0.070 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 28 | 0.070 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 24 | 0.070 |
Why?
|
| Protein Binding | 4 | 2018 | 1560 | 0.070 |
Why?
|
| Head | 1 | 2008 | 131 | 0.070 |
Why?
|
| Neural Conduction | 2 | 2010 | 72 | 0.070 |
Why?
|
| Caprylates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 1083 | 0.070 |
Why?
|
| Ependymoma | 1 | 2007 | 29 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 580 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2008 | 88 | 0.070 |
Why?
|
| Sarcolemma | 3 | 2014 | 32 | 0.070 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 362 | 0.070 |
Why?
|
| Fibrosis | 1 | 2008 | 246 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 341 | 0.070 |
Why?
|
| Endocytosis | 1 | 2008 | 186 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 232 | 0.070 |
Why?
|
| Cell Nucleus | 3 | 2019 | 623 | 0.070 |
Why?
|
| Arteries | 1 | 2008 | 181 | 0.070 |
Why?
|
| Dystrophin | 1 | 2007 | 25 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 156 | 0.060 |
Why?
|
| Action Potentials | 1 | 2010 | 618 | 0.060 |
Why?
|
| Amyloid | 1 | 2007 | 105 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 482 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2008 | 208 | 0.060 |
Why?
|
| Wilms Tumor | 1 | 2006 | 37 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2007 | 342 | 0.060 |
Why?
|
| Muscle Weakness | 2 | 2021 | 67 | 0.060 |
Why?
|
| Muscles | 1 | 2007 | 193 | 0.060 |
Why?
|
| Epilepsy | 1 | 2010 | 451 | 0.060 |
Why?
|
| Chondrocalcinosis | 1 | 2006 | 8 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2006 | 31 | 0.060 |
Why?
|
| Microglia | 2 | 2017 | 124 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 240 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2007 | 233 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2006 | 66 | 0.060 |
Why?
|
| Neurofibroma | 1 | 2005 | 12 | 0.060 |
Why?
|
| Heterozygote | 2 | 2018 | 382 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2006 | 162 | 0.060 |
Why?
|
| raf Kinases | 1 | 2025 | 15 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 209 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 2473 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2025 | 50 | 0.060 |
Why?
|
| Trans-Activators | 2 | 2005 | 446 | 0.060 |
Why?
|
| Crystallization | 1 | 2006 | 216 | 0.060 |
Why?
|
| Tunica Intima | 1 | 2005 | 61 | 0.060 |
Why?
|
| Blood Vessels | 1 | 2005 | 92 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 145 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2009 | 416 | 0.060 |
Why?
|
| Electric Stimulation | 2 | 2020 | 397 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2013 | 138 | 0.060 |
Why?
|
| Neuroimmunomodulation | 1 | 2004 | 13 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2010 | 677 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2025 | 82 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2009 | 705 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 908 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 416 | 0.050 |
Why?
|
| Cell Line | 3 | 2019 | 2533 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 1092 | 0.050 |
Why?
|
| Fibroblasts | 3 | 2014 | 777 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2090 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2024 | 41 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2007 | 356 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2025 | 162 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 713 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2417 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 395 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 76 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2024 | 107 | 0.050 |
Why?
|
| Steroids | 2 | 2018 | 174 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 256 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 191 | 0.050 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2024 | 121 | 0.050 |
Why?
|
| Paraparesis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2004 | 467 | 0.050 |
Why?
|
| Radiculopathy | 1 | 2002 | 40 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 2641 | 0.050 |
Why?
|
| Cell Movement | 2 | 2016 | 816 | 0.050 |
Why?
|
| SOX9 Transcription Factor | 1 | 2022 | 28 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2022 | 51 | 0.050 |
Why?
|
| Neurons | 1 | 2010 | 1653 | 0.050 |
Why?
|
| Risk Factors | 2 | 2024 | 5960 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2022 | 212 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 2 | 2014 | 402 | 0.040 |
Why?
|
| Homeostasis | 2 | 2018 | 467 | 0.040 |
Why?
|
| Disease Progression | 3 | 2013 | 1564 | 0.040 |
Why?
|
| Proteins | 1 | 2007 | 816 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2008 | 1375 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 20 | 0.040 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 17 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 411 | 0.040 |
Why?
|
| Integrin beta3 | 1 | 2021 | 32 | 0.040 |
Why?
|
| Femur | 1 | 2021 | 108 | 0.040 |
Why?
|
| Protein Aggregates | 1 | 2021 | 28 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 134 | 0.040 |
Why?
|
| Apoptosis | 3 | 2014 | 1760 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2001 | 333 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 104 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2001 | 111 | 0.040 |
Why?
|
| Phosphenes | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2001 | 154 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 312 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2024 | 374 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 247 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 55 | 0.040 |
Why?
|
| Pedigree | 2 | 2014 | 982 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2020 | 27 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2001 | 310 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2480 | 0.040 |
Why?
|
| Endosomes | 2 | 2010 | 86 | 0.040 |
Why?
|
| Ovary | 1 | 2021 | 268 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2001 | 509 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 246 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1010 | 0.040 |
Why?
|
| Pregnancy, Twin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2019 | 23 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1195 | 0.040 |
Why?
|
| Lysosomes | 2 | 2010 | 124 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2019 | 40 | 0.040 |
Why?
|
| Mice, Mutant Strains | 2 | 2009 | 232 | 0.040 |
Why?
|
| Twins | 1 | 2019 | 65 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2001 | 527 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 66 | 0.040 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 219 | 0.040 |
Why?
|
| KRIT1 Protein | 1 | 2019 | 62 | 0.040 |
Why?
|
| Regeneration | 2 | 2010 | 161 | 0.040 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2019 | 179 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2009 | 9173 | 0.040 |
Why?
|
| Decompression, Surgical | 1 | 2020 | 168 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 102 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 49 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2019 | 288 | 0.030 |
Why?
|
| Fetus | 1 | 2019 | 239 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 2 | 2009 | 227 | 0.030 |
Why?
|
| Macrophages | 2 | 2016 | 626 | 0.030 |
Why?
|
| Synaptic Vesicles | 1 | 2018 | 40 | 0.030 |
Why?
|
| Cryoglobulinemia | 1 | 2017 | 5 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2018 | 294 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 106 | 0.030 |
Why?
|
| Sural Nerve | 1 | 2017 | 18 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 5585 | 0.030 |
Why?
|
| Genotype | 2 | 2014 | 1882 | 0.030 |
Why?
|
| Tics | 1 | 2017 | 5 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 521 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 504 | 0.030 |
Why?
|
| Myopia | 1 | 2017 | 10 | 0.030 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2017 | 19 | 0.030 |
Why?
|
| Inhibins | 1 | 2017 | 34 | 0.030 |
Why?
|
| Cervical Cord | 1 | 2017 | 16 | 0.030 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 11 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2018 | 196 | 0.030 |
Why?
|
| Thymus Hyperplasia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Receptors, CCR4 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Melanocytes | 1 | 2017 | 60 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 4153 | 0.030 |
Why?
|
| Gout | 1 | 2017 | 75 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 750 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Ankle | 1 | 2016 | 21 | 0.030 |
Why?
|
| Face | 1 | 2017 | 115 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 706 | 0.030 |
Why?
|
| Pyramidal Cells | 1 | 2017 | 89 | 0.030 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 58 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 132 | 0.030 |
Why?
|
| tau Proteins | 1 | 2016 | 98 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 901 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1010 | 0.030 |
Why?
|
| Follistatin | 1 | 2015 | 7 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2015 | 53 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2020 | 824 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2016 | 90 | 0.030 |
Why?
|
| Immunodominant Epitopes | 1 | 2015 | 23 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 85 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2015 | 110 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2018 | 469 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 186 | 0.030 |
Why?
|
| Gliosis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Kyphosis | 1 | 2014 | 26 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 215 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2015 | 121 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 930 | 0.030 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2014 | 32 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2014 | 25 | 0.030 |
Why?
|
| Longevity | 1 | 2014 | 60 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2015 | 171 | 0.030 |
Why?
|
| Caveolin 3 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 3040 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 106 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 180 | 0.030 |
Why?
|
| Convection | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 944 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 34 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 280 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2013 | 41 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2014 | 280 | 0.020 |
Why?
|
| Algorithms | 2 | 2014 | 2014 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2014 | 282 | 0.020 |
Why?
|
| Vaccination | 1 | 2015 | 311 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 392 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2014 | 281 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2014 | 200 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 611 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2012 | 35 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 740 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 363 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2012 | 53 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 385 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1157 | 0.020 |
Why?
|
| Polymers | 1 | 2013 | 220 | 0.020 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2012 | 40 | 0.020 |
Why?
|
| Cell Division | 1 | 2013 | 705 | 0.020 |
Why?
|
| Rabbits | 1 | 2012 | 639 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2015 | 565 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 777 | 0.020 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2010 | 6 | 0.020 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2010 | 15 | 0.020 |
Why?
|
| Bicuculline | 1 | 2010 | 19 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2010 | 43 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2010 | 38 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2010 | 50 | 0.020 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 1030 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 252 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2010 | 116 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 481 | 0.020 |
Why?
|
| Electrodiagnosis | 1 | 2010 | 8 | 0.020 |
Why?
|
| Cardiotoxins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Pupil | 1 | 2010 | 20 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2010 | 82 | 0.020 |
Why?
|
| Mice, Inbred mdx | 1 | 2010 | 16 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2010 | 41 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2010 | 38 | 0.020 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Myoblasts, Skeletal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2009 | 26 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 366 | 0.020 |
Why?
|
| Sulfonylurea Receptors | 1 | 2009 | 50 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2010 | 278 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2010 | 142 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2781 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1010 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 286 | 0.020 |
Why?
|
| Lamins | 1 | 2008 | 6 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 563 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 295 | 0.020 |
Why?
|
| DNA | 1 | 2014 | 1332 | 0.020 |
Why?
|
| Neurosurgery | 1 | 2011 | 143 | 0.020 |
Why?
|
| Transferrin | 1 | 2008 | 21 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2008 | 39 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1763 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2008 | 34 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 592 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2008 | 112 | 0.020 |
Why?
|
| Magnetics | 1 | 2008 | 43 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 2008 | 34 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2009 | 253 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2009 | 302 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 120 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 205 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 240 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2008 | 215 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 358 | 0.020 |
Why?
|
| Aldehydes | 1 | 2007 | 21 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2008 | 360 | 0.020 |
Why?
|
| Micelles | 1 | 2007 | 53 | 0.020 |
Why?
|
| Pentosyltransferases | 1 | 2007 | 36 | 0.020 |
Why?
|
| Asparagine | 1 | 2007 | 29 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2007 | 102 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2008 | 88 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2007 | 67 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 394 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2008 | 281 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 744 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2008 | 181 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2494 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2006 | 131 | 0.010 |
Why?
|
| Gelsolin | 1 | 2005 | 11 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2007 | 830 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 48 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2006 | 118 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2005 | 242 | 0.010 |
Why?
|
| Niacinamide | 1 | 2005 | 102 | 0.010 |
Why?
|
| Benzenesulfonates | 1 | 2005 | 50 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2009 | 873 | 0.010 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 99 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2007 | 382 | 0.010 |
Why?
|
| Genes, Synthetic | 1 | 2004 | 7 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 125 | 0.010 |
Why?
|
| Lac Operon | 1 | 2004 | 46 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2004 | 59 | 0.010 |
Why?
|
| Cerebellar Ataxia | 1 | 2004 | 27 | 0.010 |
Why?
|
| STAT1 Transcription Factor | 1 | 2004 | 58 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 2090 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 37 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 594 | 0.010 |
Why?
|
| Echocardiography | 1 | 2009 | 1004 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 281 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 213 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1349 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 2004 | 107 | 0.010 |
Why?
|
| Astrocytes | 1 | 2004 | 151 | 0.010 |
Why?
|
| Leukocytes | 1 | 2004 | 218 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 319 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 182 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 564 | 0.010 |
Why?
|
| Cerebellum | 1 | 2004 | 253 | 0.010 |
Why?
|
| Stroke | 1 | 2008 | 1087 | 0.010 |
Why?
|